Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · IEX Real-Time Price · USD
1.240
+0.010 (0.81%)
At close: Mar 28, 2024, 3:58 PM
1.250
+0.010 (0.81%)
After-hours: Mar 28, 2024, 4:59 PM EDT

Company Description

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.

It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.

Estrella Immunopharma, Inc. is based in EmeryVille, California.

Estrella Immunopharma, Inc.
Estrella Immunopharma logo
Country United States
Founded 2021
Industry Biotechnology
Sector Healthcare
CEO Dr. Cheng Liu Ph.D.

Contact Details

Address:
5858 Horton Street, Suite 370
Emeryville, California 94608
United States
Phone (510) 318-9098
Website estrellabio.com

Stock Details

Ticker Symbol ESLA
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001844417
ISIN Number US2975841048
Employer ID 86-1314502
SIC Code 2836

Key Executives

Name Position
Dr. Cheng Liu Ph.D. Chief Executive Officer, President and Director
Jiandong Xu Chief Financial Officer

Latest SEC Filings

Date Type Title
Mar 11, 2024 424B3 Prospectus
Mar 11, 2024 8-K Current Report
Mar 7, 2024 424B3 Prospectus
Mar 7, 2024 8-K Current Report
Feb 16, 2024 424B3 Prospectus
Feb 14, 2024 10-Q Quarterly Report
Feb 12, 2024 424B3 Prospectus
Feb 2, 2024 8-K Current Report
Jan 30, 2024 8-K Current Report
Dec 28, 2023 EFFECT Notice of Effectiveness